# Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

> **NCT00640861** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 45 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** CpG oligodeoxynucleotide
- **BIOLOGICAL:** HER-2/neu peptide vaccine
- **BIOLOGICAL:** MUC-1 peptide vaccine
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** sargramostim
- **OTHER:** immunoenzyme technique
- **OTHER:** immunologic technique

## Key facts

- **NCT ID:** NCT00640861
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-28
- **Primary completion:** 2015-04-21
- **Final completion:** 2015-04-21
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2018-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640861, "Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00640861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*